US 12,391,676 B2
BRD4-JAK2 inhibitors
Ernst Schönbrunn, Tampa, FL (US); Nicholas J. Lawrence, Tampa, FL (US); Harshani R. Lawrence, Tampa, FL (US); and Gary Reuther, Tampa, FL (US)
Assigned to H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US)
Appl. No. 17/274,265
Filed by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US)
PCT Filed Sep. 9, 2019, PCT No. PCT/US2019/050148
§ 371(c)(1), (2) Date Mar. 8, 2021,
PCT Pub. No. WO2020/051572, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/728,436, filed on Sep. 7, 2018.
Prior Publication US 2022/0119370 A1, Apr. 21, 2022
Int. Cl. C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01)
CPC C07D 403/12 (2013.01) [C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01)] 10 Claims
 
1. A compound selected from

OG Complex Work Unit Chemistry
or a salt thereof.